Yuen A W
Wellcome Research Laboratories, Beckenham, Kent, England.
Epilepsia. 1994;35 Suppl 5:S33-6. doi: 10.1111/j.1528-1157.1994.tb05964.x.
Lamotrigine (LTG) is a chemically novel antiepileptic drug (AED) that blocks voltage-sensitive sodium channels, leading to inhibition of neurotransmitter release, principally glutamate. LTG is active in a wide range of pharmacologic models of epilepsy, demonstrating a potency and duration of action generally superior to currently available AEDs. Preliminary evidence of efficacy was provided by single-dose studies showing effects on reducing interictal spike activity and photoconvulsive response. A total of eight randomized, double-blind, placebo-controlled, crossover trials have established the efficacy of LTG in patients with refractory partial epilepsy. Literature reports suggest LTG also is effective in patients with idiopathic generalized epilepsy, including absence seizures, and in patients with Lennox-Gastaut syndrome. Other reports suggest that LTG is useful in the pediatric population, and an interim report of an open monotherapy trial suggests that the efficacy of LTG was comparable to that of carbamazepine (CBZ) but the adverse experiences leading to discontinuation were less frequent.
拉莫三嗪（LTG）是一种化学结构新颖的抗癫痫药物（AED），它可阻断电压敏感性钠通道，从而抑制神经递质释放，主要是谷氨酸的释放。LTG在多种癫痫药理学模型中均有活性，其效力和作用持续时间总体上优于目前可用的抗癫痫药物。单剂量研究显示其对减少发作间期棘波活动和光惊厥反应有作用，提供了疗效的初步证据。共有八项随机、双盲、安慰剂对照、交叉试验证实了LTG对难治性部分性癫痫患者的疗效。文献报告表明，LTG对特发性全身性癫痫患者（包括失神发作）以及伦诺克斯 - 加斯托综合征患者也有效。其他报告提示，LTG在儿科患者中有用，一项开放单药治疗试验的中期报告表明，LTG的疗效与卡马西平（CBZ）相当，但导致停药的不良事件发生率较低。
